Fei Fei, M.D.

Fei-Fei
Pathologist
Clinical Expertise
Molecular Biology
Other Languages Spoken
Mandarin
Appointments
Assistant Clinical Professor, Department of Pathology

Molecular pathologist Fei Fei, M.D., focuses on providing the accurate and timely diagnoses that are essential to effective treatment and the best-possible outcomes for patients. In the process, she attends to the specific needs of each patient, considering their unique medical history, symptoms and circumstances.

Dr. Fei first became interested in oncology while conducting a research project about drug-resistant leukemia when she was a resident in anatomic and clinical pathology at the University of Alabama at Birmingham, where she was supported by an institutional grant. She joined City of Hope in 2023 with 38 peer-reviewed biomedical publications to her credit. During her fellowship training in molecular genetic pathology at Stanford University, she was recognized with a Pathology Trainee Mentored Award.

Away from the lab, Dr. Fei’s pastimes include spending time with family, cooking, reading and traveling.

Location
Education & Experience
Board Certification
  • 2021, American Board of Pathology – Anatomic and Clinical Pathology
Degrees
  • 2006, Master of Clinical Medicine, Internal Medicine (Hematology), Southeast University, Nanjing, China
  • 2003, Bachelor of Medicine, Southeast University, Nanjing, China
Fellowship
  • 2023, Fellowship, Molecular Genetic Pathology, Stanford University, Stanford, California
  • 2022, Fellowship, Hematopathology, Stanford University, Stanford, California
  • 2015, Postdoctoral Fellowship, Hematology/Oncology, Children’s Hospital Los Angeles, University of Southern California, Los Angeles, California
  • 2008, Postdoctoral Fellowship, Hematology/Oncology, Ulm University, Ulm, Germany
Residency
  • 2021, Anatomic and Clinical Pathology, University of Alabama, Birmingham, Alabama
  • 2006, Hematology, Zhong Da Hospital, Southeast University, Nanjing, China
Professional Experience
  • 2023-present, Assistant Clinical Professor, Department of Pathology, City of Hope, Duarte, California
Awards & Memberships

Awards

  • 2022, Pathology Trainee Mentored Award, Stanford University
  • 2018, Adam Grant (Resident research grant), The University of Alabama at Birmingham

Memberships

  • 2018, United States and Canadian Academy of Pathology
  • 2017, College of American Pathologists
  • 2017, American Society for Clinical Pathology
  • 2012, American Association for Cancer Research
Publications
  • Fei F, Kiruthiga KG, Younes S, Natkunam Y. EBV-positive nodular lymphocyte predominant Hodgkin lymphoma: A single institution experience. Accepted (Human Path).
  • Fei F, Natkunam Y, Zehnder JL, Stehr H, Gratzinger D. Diagnostic impact of next-generation sequencing panels for lymphoproliferative neoplasms on small-volume biopsies. Am J Clin Pathol. 2022 May 12:aqac045. doi: 10.1093/ajcp/aqac045.
  • Fei F, Siegal GP, Wei S. Characterizing clinicopathologic features of estrogen receptor-positive/progesterone receptor-negative breast cancers. Clinical Breast Cancer. 2022, July. doi.org/10.1016/j.clbc.2022.07.001.
  • Fei F, Liedtke M, Oscar S. Case report: mature plasmacytoid dendritic cell proliferation associated with a lymphoid neoplasm. Front. Oncol. 2022 July. doi.org/10.3389/fonc.2022.903113.
  • Bum-Erdene K, Collins PM, Hugo MW, Tarighat SS, Fei F, Kishor C, Leffler H, Nilsson UJ, Groffen J, Grice ID, Heisterkamp N, Blanchard H. Novel selective galectin-3 antagonists are cytotoxic to acute lymphoblastic leukemia. J Med Chem. 2022 Apr 28;65(8):5975-5989.
  • Tarighat SS, Fei F, Joo EJ, Abdel-Azim H, Yang L, Geng H, Bum-Erdene K, Grice ID, von Itzstein M, Blanchard H, Heisterkamp N. Overcoming microenvironment-mediated chemoprotection through stromal galectin-3 inhibition in acute lymphoblastic leukemia. Int J Mol Sci. 2021 Nov 10;22(22):12167.
  • Fei F, Siegal GP, Wei S. Characterization of estrogen receptor-low-positive breast cancer. Breast Cancer Res Treat. 2021 Jul;188(1):225-235.
  • Kulkarni T, Valentine VG, Fei F, Tran-Nguyen TK, Quesada-Arias LD, Mkorombindo T, Pham HP, Simmons SC, Dsouza KG, Luckhardt T, Duncan SR. Correlates of survival after autoantibody reduction therapy for acute IPF exacerbations. PLoS One. 2021 Nov 23;16(11):e0260345.
  • Fei F, Reddy V, Rosenblum F. Secondary primary malignancies in patients with multiple myeloma: A single institution experience. Hematol Oncol. 2021 Dec;39(5):674-679.
  • Fei F, Prieto Granada CN, Harada S, Siegal GP, Wei S. Round cell tumor with a myxoid matrix harboring a PHF1-TFE3 fusion: Myoepithelial neoplasm or ossifying fibromyxoid tumor? Pathol Res Pract. 2021 Sep; 225:153578.